MENU
INSM
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

INSM stock forecast, quote, news & analysis

Insmed Inc is a biopharmaceutical company... Show more

Industry: #Biotechnology
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
Oct 12, 2026

Why Insmed (INSM) Stock Is Down -22% in the Last 30 Days

Key Takeaways

  • Insmed shares have declined roughly 22% over the last 30 days, falling from about $129 to approximately $100 and reversing most of the stock's summer rally.
  • The pullback followed the company's October 5 announcement that CFO Sara Bonstein will step down on October 30, even as full-year 2026 revenue guidance was reaffirmed.
  • A Wolfe Research downgrade to Peer Perform, tied to questions about how quickly Brinsupri's addressable market can expand, added selling pressure in October.
  • Several other analysts—including Morgan Stanley, RBC Capital, UBS, and H.C. Wainwright—reiterated Buy ratings, citing rising Brinsupri prescriptions.
  • The prior quarter was defined by a roughly 34% single-session surge on August 6 after strong second-quarter results, followed by a multi-week give-back.

Insmed (INSM) Company Overview and Market Position

Insmed Incorporated is a global biopharmaceutical company headquartered in Bridgewater, New Jersey, focused on first- and best-in-class therapies for serious diseases. Its commercial portfolio is built around two approved respiratory medicines. Brinsupri (brensocatib) is the first and only FDA-approved treatment for non-cystic fibrosis bronchiectasis (NCFB), a chronic, neutrophil-driven lung disease; it is a first-in-class DPP1 inhibitor that received U.S. approval in August 2025. Arikayce (amikacin liposome inhalation suspension) is an inhaled therapy for refractory Mycobacterium avium complex (MAC) lung disease. The company also advances a late-stage pipeline led by treprostinil palmitil inhalation powder (TPIP) for pulmonary hypertension and pulmonary fibrosis. Investors follow INSM closely because its growth hinges on the commercial ramp of Brinsupri and on regulatory milestones that could expand Arikayce's label.

Insmed (INSM) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, INSM has fallen about 22%, from a close of $129.41 on September 11 to $100.60 as of the October 9 close. The decline was broad-based rather than a single-day event, with shares grinding lower through late September and accelerating in early October.

The trailing quarter tells a more volatile story. The stock began the period near $118 in early July, surged roughly 34% in one session to about $132 on August 6 following second-quarter earnings, and has since given back those gains and more. From early-July levels, INSM is down approximately 15%, leaving shares well below their 52-week high of $212.75.

What Drove INSM Stock Price in the Last 30 Days

Several factors converged during the 30-day decline. On October 5, Insmed announced that CFO Sara Bonstein will step down on October 30 after nearly seven years, while reaffirming full-year 2026 revenue guidance of $1.25 billion to $1.40 billion for Brinsupri and $450 million to $470 million for Arikayce. The transition was described as unrelated to any accounting or operational disagreement, but executive changes can still weigh on sentiment for a high-growth, unprofitable biotech.

In mid-October, Wolfe Research downgraded the stock to Peer Perform from Outperform, citing concerns that identifying comorbid patients to broaden Brinsupri's market may stretch beyond mid-2027. The move contrasted with reiterated Buy ratings from Morgan Stanley (with a $218 price target), RBC Capital ($195), UBS, and H.C. Wainwright, several of which highlighted sequentially rising Brinsupri prescriptions. The combination of profit-taking after the summer rally, the CFO transition, and a more cautious view from one sell-side firm drove the pullback.

What Drove INSM Stock Performance Over the Last Quarter

The quarter's defining catalyst was the August 6 second-quarter report. Insmed posted total revenue of $425.5 million, up 296% year over year, driven by Brinsupri revenue of $309.2 million—up 49% sequentially—and raised its full-year Brinsupri guidance to $1.25 billion to $1.40 billion. The company also lifted its combined peak-sales estimate for its three lead programs to more than $14 billion, and shares jumped about 34% that day.

Other developments shaped the longer-term narrative. In July, Insmed submitted a supplemental new drug application for Arikayce in newly diagnosed MAC lung disease, which the FDA later accepted under Priority Review with a target action date of January 28, 2027. The company has also pointed to a Japanese regulatory decision for brensocatib in the second half of 2026. Despite these catalysts, the stock has traded lower as investors weighed launch-expansion timelines and near-term execution risk against strong commercial momentum.

Trending AI Robots

Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots designed to identify and act on market opportunities across thousands of tickers. Tickeron offers hundreds of these automated systems, but only the top-performing and most relevant bots appear in this featured section, giving traders a focused view of strategies that are currently resonating with market conditions. The bots vary widely in their approach, holding timeframe, and performance metrics, so the curated list spans different trading styles rather than a single strategy. Investors tracking volatile names such as INSM can use the page to explore automated tools that monitor price action and technical signals. Visit the Trending AI Robots page to review the available bots and their latest performance data.

INSM Stock Forecast Drivers: What Investors Should Watch Next

  • Third-quarter earnings scheduled for October 29, including updated Brinsupri and Arikayce revenue and any change to full-year guidance.
  • The Japanese regulatory decision for brensocatib, expected in the second half of 2026.
  • The FDA's Priority Review of the Arikayce sNDA, with a PDUFA target action date of January 28, 2027.
  • Brinsupri prescription trends, payer access, and the pace of diagnosis-expansion initiatives.
  • Pipeline progress, including the Phase 3 TPIP programs and earlier-stage candidates.

Macroeconomic conditions, evolving U.S. healthcare policy, and sector-level risk appetite could also influence valuations across the biotechnology space.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for INSM with price predictions
Nov 13, 2026

INSM's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for INSM turned positive on October 27, 2026. Looking at past instances where INSM's MACD turned positive, the stock continued to rise in 44 of 52 cases over the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on INSM as a result. In 77 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

INSM moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for INSM crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.

Following a +4.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where INSM advanced for three days, in 201 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.

Bearish Trend Analysis

The 10-day RSI Indicator for INSM moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 25 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

INSM broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for INSM entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. INSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 52 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.982) is normal, around the industry mean (3.498). P/E Ratio (-27.768) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (23.148) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a biopharmaceutical company

Industry Biotechnology

Industry
Biotechnology
Address
700 US Highway 202/206
Phone
+1 908 977-9900
Employees
1664
Web
https://www.insmed.com
Why Insmed (INSM) Stock Is Down -22% in the Last 30 Days